PGC-MG7 combination could be used as a follow-up panel for monitoring dynamical progression of gastric precancerous diseases

作     者：Peifang Ning Liping Sun Nannan Dong Yuan Yuan Peifang Ning;Liping Sun;Nannan Dong;Yuan Yuan

作者机构：Tumor Etiology and Screening Department of Cancer Institute and General Surgerythe First Hospital of China Medical UniversityShenyang 110001China Key Laboratory of Cancer Etiology and Prevention in Liaoning Education Departmentthe First Hospital of China Medical UniversityShenyang 110001China Pathologic Department of Cancer Hospital of China Medical University(Liaoning Cancer Hospital&Institute)Shenyang 110042China 

出 版 物：《Chinese Journal of Cancer Research》 (中国癌症研究（英文版）)

年 卷 期：2020年第32卷第1期

页      面：89-95页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by grants from the National Science and Technology Support Program (No. 2015BAI13B07) the Science Technology Project in Liaoning Province (No. 2012225016). 

主　　题：Pepsinogen C gastric cancer-associated antigen MG7 gastric cancer diagnosis carcinogenesis 

摘      要：Objective: The aim of this study was to investigate the value of the combined expression of the gastric mucosal differentiation protein pepsinogen C(PGC) and gastric cancer(GC)-associated antigen MG7 for the diagnosis of GC and prediction of the development from precancerous conditions to GC.Methods: The gastric mucosal biopsies of 285 subjects enrolled from a region with a high incidence of GC were obtained and histopathologically examined. Subjects testing negative for GC(n=208) were followed up from 1998 to 2015. The levels of PGC and MG7 in the biopsies were determined by immunohistochemistry.Results: PGC was positive in 91.4% of the non-atrophic gastritis, 26.5% of the atrophic gastritis, and 0% of the GC. MG7 was positive in 15.0% of the non-atrophic gastritis, 82.4% of the atrophic gastritis, and 94.8% of the GC. The non-atrophic gastritis group was predominantly PGC+MG7-. The atrophic gastritis and GC groups were predominantly PGC-MG7+. The rate of GC in subjects with PGC-MG7+ staining was 113.4-fold higher [95% confidence interval(95% CI): 15.3-869.4, P0.001] than that in subjects with other staining patterns.The sensitivity and specificity of the PGC-MG7+ pattern were 92.2% and 78.8% for the detection of GC and77.2% and 97.9% for GC and precancerous disease, respectively. In the follow-up cohort of non-GC subjects, the risk of developing GC was higher in those with the PGC-MG7+ staining pattern.Conclusions: Our data suggest that the PGC-MG7+ pattern can be employed as a useful follow-up panel for detecting individuals with a high risk of GC, and the dynamic assessment of the follow-up panel needs multi-centre large-scale validation in the future.